KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Fulgent Genetics (FLGT) Net Margin (2016 - 2025)

Fulgent Genetics' Net Margin history spans 11 years, with the latest figure at 28.1% for Q4 2025.

  • For Q4 2025, Net Margin fell 2038.0% year-over-year to 28.1%; the TTM value through Dec 2025 reached 18.75%, down 369.0%, while the annual FY2025 figure was 18.75%, 369.0% down from the prior year.
  • Net Margin for Q4 2025 was 28.1% at Fulgent Genetics, down from 7.86% in the prior quarter.
  • Across five years, Net Margin topped out at 55.84% in Q1 2021 and bottomed at 315.32% in Q4 2022.
  • The 5-year median for Net Margin is 13.87% (2023), against an average of 21.51%.
  • The largest annual shift saw Net Margin crashed -35651bps in 2022 before it surged 17403bps in 2024.
  • A 5-year view of Net Margin shows it stood at 41.2% in 2021, then plummeted by -865bps to 315.32% in 2022, then soared by 42bps to 181.76% in 2023, then surged by 96bps to 7.73% in 2024, then plummeted by -264bps to 28.1% in 2025.
  • Per Business Quant, the three most recent readings for FLGT's Net Margin are 28.1% (Q4 2025), 7.86% (Q3 2025), and 23.17% (Q2 2025).